sebra-shutterstock-com-2
sebra / Shutterstock.com
26 November 2015AmericasVaruni Paranavitane

Court reports: Warner-Lambert v Sandoz

Since the early 1980s, the European Patent Office has granted second medical use patents for new uses of known pharmaceutical products. Second medical use patents can cover a new indication, a new dosage regimen, or a new method of treatment. For example, Asp irin, possibly the world’s most commonly used drug, was first discovered for its analgesic properties; only subsequently were its anticoagulant properties discovered. The interpretation of second medical use claims, and consequently the approach to infringement of these claims by courts, varies from jurisdiction to jurisdiction and is a developing area of the law.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
27 February 2026   The companies have agreed to dismiss their long-running patent fight over tumour-informed liquid biopsy technology, closing a high-stakes chapter in the fast-growing MRD testing market—while leaving the door open to future claims.
Americas
26 February 2026   As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.
Americas
26 February 2026   In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.